M Z Atassi Selected Research

Histocompatibility Antigens Class II

1/2001

On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

M Z Atassi Research Topics

Disease

3	Myasthenia Gravis 02/2011 - 03/2000
2	Torticollis (Wryneck) 12/2015 - 12/2006
2	Autoimmune Diseases (Autoimmune Disease) 01/2001 - 03/2000
2	Experimental Autoimmune Myasthenia Gravis (Autoimmune Experimental Myasthenia Gravis) 06/2000 - 01/2000
1	Thymoma (Thymic Carcinoma) 02/2011
1	Disease Susceptibility (Diathesis) 01/2001

Drug/Important Bio-Agent (IBA)

4	Cholinergic ReceptorsIBA 02/2011 - 01/2000
2	EpitopesIBA 12/2015 - 01/2001
2	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 01/2001 - 06/2000
2	AutoantibodiesIBA 01/2001 - 03/2000
2	Peptides (Polypeptides)IBA 01/2001 - 06/2000
1	incobotulinumtoxinA FDA Link 12/2015
1	HLA-DQ Antigens (HLA-DQ)IBA 02/2011
1	batrachotoxinin A 20-alpha-benzoateIBA 12/2006
1	rimabotulinumtoxinB FDA Link 12/2006
1	Blocking AntibodiesIBA 12/2006
1	Histocompatibility Antigens Class IIIBA 01/2001
1	AntibodiesIBA 01/2001
1	Monoclonal AntibodiesIBA 06/2000
1	AntigensIBA 03/2000